FINWIRES · TerminalLIVE
FINWIRES

Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says

By

Jazz Pharmaceuticals' (JAZZ) shares are up about 45% year to date, but may still have the potential for moderate further appreciation, RBC Capital Markets said in a note Friday.

As the company gradually enters a "more fulsome biotech era," its shares will likely "continue to re-rate, driven by higher-growth opportunities" like the one offered by its cancer drug Ziihera, the note said.

RBC said that while some cash flow analyses may indicate that the company's shares are fairly valued, it believes that the stock may see more upside, which would take it closer in line with biotech firms, due to its "ongoing momentum, still relatively undemanding multiple, and further balance sheet optionality."

The investment firm also said that it is now more accurately reflecting the value of Jazz's cancer drug Ziihera by including the drug's "pan-tumor potential," which RBC believes may contribute about $500 million by 2035, as well as modeling a recent financing.

RBC has an outperform rating on Jazz and lifted the company's price target to $299 from $277.

Price: $246.55, Change: $-4.55, Percent Change: -1.81%

Related Articles

Wire

Update: PagerDuty Q2 Adjusted Earnings, Revenue Rise; Company Plans 15% Workforce Cut

(Updates with job cuts in the penultimate paragraph.)PagerDuty (PD) reported Thursday Q2 adjusted earnings of $0.32 per diluted share, up from $0.30 a year earlier.Analysts polled by FactSet expected $0.31.Revenue for the quarter ended July 31 rose to $124.4 million from $123.4 million a year earlier.Analysts projected $123.3 million.The company expects Q3 adjusted EPS of $0.34 to $0.36 on revenue of $123 million to $125 million. Analysts project EPS of $0.34 on revenue of $124.4 million.PagerDuty expects 2027 adjusted EPS of $1.33 to $1.37 on revenue of $491.5 million to $496.5 million. Analysts project EPS of $1.32 on revenue of $494.2 million.In a regulatory filing, the company said it plans to cut 15% of its workforce as part of a restructuring and record non-recurring charges of $5.5 million to $7.5 million related to the move.PagerDuty shares fell 2.4% in after-hours trading.

$PD
Wire

Affirm Fiscal Q4 Earnings, Revenue Rise; Shares Gain After-Hours

Affirm Holdings (AFRM) reported fiscal Q4 net income late Thursday of $4.62 per diluted share, up from $0.20 a year earlierAnalysts polled by FactSet expected $0.35, if comparable.Revenue for the quarter ended June 30 was $1.17 billion, up from $876.4 million a year earlier.Analysts expected $1.11 billion.For fiscal Q1, the company expects revenue of $1.19 billion to $1.22 billion.Analysts are looking for $1.16 billion.Shares rose over 6% in after-hours activity.

$AFRM
Wire

Elastic Q1 Adjusted Earnings, Revenue Rise; Shares Surge After Hours

Elastic (ESTC) reported fiscal Q1 non-GAAP earnings late Thursday of $0.70 per diluted share, up from $0.60 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended July 31 rose to $478.1 million from $415.3 million a year earlier.Analysts projected $469.7 million.The company expects fiscal Q2 non-GAAP EPS of $0.80 to $0.82 on revenue of $486 million to $487 million.Analysts project EPS of $0.79 on revenue of $483.5 million.Elastic boosted fiscal 2027 guidance to non-GAAP EPS of $3.29 to $3.37 on revenue of $1.998 billion to $2.01 billion, up from the prior forecast of EPS of $3.21 to $3.29 on revenue of $1.985 billion to $2 billion.Analysts expect EPS of $3.24 on revenue of $1.996 billion.Elastic shares jumped 22% in after-hours trading.

$ESTC